Background -The sensitivity and accuracy of death certificates and mortality data as sources ofpopulation based data on the occurrence of interstitial lung diseases has received limited attention. To determine the usefulness of these data sources, death certificates and mortality data from patients in New Mexico were examined.
Methods Several different sources were used to identify patients with interstitial lung diseases aged 18 years and older who were residents of Bernalillo County including pulmonary and primary care physicians, pathology reports, hospital discharge diagnoses, state mortality data, and necropsies. After referral of a potential case of interstitial lung disease to the registry a trained abstractor obtained the medical record to verify the diagnosis. Verification of the diagnosis of an interstitial lung disease required the use of a specific interstitial lung disease term by a clinician caring for the patient. If the clinician used ambiguous language such as "questionable," "possible," or "suggests," or the abstractor had any questions, the chart was also reviewed by one of the authors (DBC). A detailed description of data collection methods for the registry has been described previously.7
The vital status of 385 cases identified from the registry was determined by review of medical records and of State of New Mexico mortality data to 1 August 1994. Records of death certificates and state mortality data were obtained for each death. Death certificate data, including all information on the cause of death from Part I(a) to I(d) ("immediate" and three "underlying" causes of death) and Part II ("other significant conditions contributing to death"), were abstracted. Each cause was grouped into one of the following categories: respiratory/interstitial lung diseases, respiratory/not interstitial lung diseases, cardiovascular/cerebrovascular diseases, neoplasms, gastrointestinal diseases, renal diseases, accidents/injuries, and other diseases. Ifa cause of death was a respiratory/interstitial lung disease, the specific interstitial lung disease diagnosis was also abstracted. Death certificate information was abstracted with no knowledge of the clinical diagnoses before death or the state mortality data codes.
Sensitivity of death certificate and mortality data for detecting interstitial lung diseases was estimated by the proportion of pre-death diagnoses of interstitial lung diseases listed. Diagnostic information on the death certificate was categorised as immediate cause (Part Ia), underlying causes (Part Ib-d), other significant conditions (Part II), and ever listed (Parts Ia-d and II).
The validity of the death certificates and mortality data was determined by comparing the distribution of diagnoses of interstitial lung diseases from these data sources with the distribution of specific diagnoses before death. All analyses were performed using SAS for personal computers. In state mortality data interstitial lung diseases were the second most common cause of death (table 1) . However, the sensitivity of mortality data for identifying patients with a clinical diagnosis before death of an interstitial lung disease was only 21-7%.
Overall, 55% of study patients had a diagnosis of pulmonary fibrosis before death (table  2) , comprising post-inflammatory pulmonary fibrosis (International Classification of Diseases (ICD)-9 category 515) and idiopathic/ interstitial fibrosis (ICD-9 category 516-3). Of these, 71 8% were diagnosed as idiopathic/ interstitial fibrosis. After pulmonary fibrosis, the category of interstitial lung diseases not otherwise specified was the second most frequent diagnosis (11 6%), with "other interstitial lung diseases" being far less common.
For all 129 patients with a diagnosis of an interstitial lung disease before death, the diagnoses were infrequently listed on death certificates and state mortality data (table 2) (table 2) , we used this diagnostic category to examine further the relationship between diagnoses made before death and those listed somewhere on the death certificates or in the state mortality data. Overall, for patients with the general diagnosis of pulmonary fibrosis before death (n = 71) and with a diagnosis of an interstitial lung disease on the death certificate (n=37), 91-9% had a death certificate diagnosis consistent with pulmonary fibrosis -that is, ICD-9 category 515 (n = 12) or 516-3 (n = 22). However, for the 20 patients with a diagnosis of post-inflammatory pulmonary fibrosis made before death, only 10% appeared on the death certificate and 5% in the state mortality data. Although patients with a diagnosis made before death of idiopathic/ interstitial fibrosis were more likely to have this diagnosis listed somewhere on the death certificate (21-5%), post-inflammatory pulmonary fibrosis was listed more often somewhere on the death certificate (39 2%).
Overall, the New Mexico state mortality data diagnoses were consistent with the diagnosis of pulmonary fibrosis made before death (n = 71) in 25X4% of cases. However, in no case was the diagnosis of idiopathic/interstitial fibrosis reported as a cause of death in the state mortality data. Furthermore, the diagnosis of pulmonary fibrosis (categories 515 and 516X3) never appeared in state mortality data without evidence of a clinical diagnosis made before death.
Discussion
The results of this investigation provide quantitative information on the diagnostic sensitivity and validity of death certificates and state mortality data for describing the occurrence of interstitial lung diseases. We found that both data sources underestimated the occurrence of interstitial lung diseases, and that state mortality data -which are the basis for published mortality rates -missed nearly 80% of cases, but mortality data never overestimated their occurrence.
Several issues that may influence the interpretation ofour findings must be considered. The generally chronic nature of interstitial lung diseases is a factor that may contribute to the underestimation of such cases from mortality data as patients with these diseases may die from causes other than the interstitial lung disease. In a review of five clinical series that included 326 patients who died from idiopathic pulmonary fibrosis, Panos et alt found that 39% of patients died from respiratory failure due to the underlying lung disease. Because these results were not derived from death certificate or state mortality data, the findings are not directly comparable with the results of our investigation.
Although underestimation of the occurrence of interstitial lung diseases from death certificates and mortality data may be expected, a low concordance between the diagnoses made before death and those on the death certificates and in the mortality data raises additional concerns about the usefulness of mortality data for describing the occurrence of interstitial lung diseases. Because we relied on clinicians' diagnoses of an interstitial lung disease, inaccurate diagnoses made before death may contribute to this low concordance. This is of particular concern for the diagnoses ofpost-inflammatory pulmonary fibrosis and idiopathic pulmonary fibrosis which may be clinically similar to other interstitial lung diseases and usually require an open lung biopsy for a definitive diagnosis. Because only 7% ofsubjects in the New Mexico registry of interstitial lung diseases had an open lung biopsy,7 the role of inaccurate clinical diagnoses cannot be assessed in this investigation. Clinical diagnoses obtained by a standardised review of patients' medical records by trained abstractors7 represent our best available diagnostic information. However, because there was little reclassification of diagnoses, other than between post-inflammatory pulmonary fibrosis and idiopathic/interstitial fibrosis, inaccurate clinical diagnoses cannot explain the substantial diagnostic misclassification in death certificates and mortality data.
A greater use ofpulmonary fibrosis compared with idiopathic/interstitial fibrosis on death certificates and in coding mortality data in the USA may partly explain the trends in the nationwide mortality for these two diagnoses since 1979.5 1 Since that date, mortality rates in the USA have been higher for post-inflammatory pulmonary fibrosis than for idiopathic/interstitial fibrosis, and have shown a greater increase.
The infrequent use of the diagnostic term "idiopathic/interstitial fibrosis" in the USA may also contribute to the differences in mortality patterns compared with other countries. Hubbard et al5 have compared mortality rates since 1979 for idiopathic/interstitial fibrosis in seven countries. The mortality rates were highest for England and Wales (rate ratio = 1) and lowest for Germany (rate ratio = 0-087). In contrast, mortality from post-inflammatory pulmonary fibrosis was highest in the USA when compared with other countries. The use of different diagnostic terms with idiopathic pulmonary fibrosis in the USA and cryptogenic fibrosing alveolitis in the UK may partly explain these differences.
In a study published in 1990 Johnston et al4 determined the sensitivity of death certificates in the UK for detecting idiopathic pulmonary fibrosis among 45 patients with the disease who died during the period 1985-9. They found that 38% of the death certificates attributed death to idiopathic pulmonary fibrosis, and 56% had idiopathic pulmonary fibrosis mentioned somewhere on the death certificate. These estimates of sensitivity are higher than in our population (table 2), and suggest that physicians in the UK are more likely to use the specific diagnostic term of idiopathic pulmonary fibrosis on death certificates than physicians in New Mexico.
The results of this investigation suggest that death certificates and mortality data offer little useful information for the study of interstitial lung diseases. However, the sensitivity and validity of these data sources may vary by region within the USA and between countries because of the different patterns in completing death certificates and in coding mortality data. Furthermore, differing patterns of mortality rates in different countries' also suggest that international efforts are needed to standardise the coding of idiopathic/interstitial fibrosis and post-inflammatory pulmonary fibrosis.
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